Dean Bornilla

Dean Bornilla, Pace® Life Sciences, highlights his organization's future role in supporting biopharmaceutical development and manufacturing coast-to-coast.

Major Growth & Investment at Pace® Life Sciences

Pace® Life Sciences, a biopharmaceutical services provider, has experienced significant growth through recent acquisitions of analytical labs, substantially increasing their testing capacity and scientific expertise. Looking ahead to 2025, Pace® is undertaking key expansions at their Salem, NH, site to include sterile fill-finish capabilities for clinical trial manufacturing and at their Oakdale, MN, facility to double their biopharmaceutical analytical services. With a growing network of locations across major US pharmaceutical hubs, Pace® aims to enhance customer experience through consistent quality and timely delivery. The company anticipates continued growth through both organic initiatives and further acquisitions, supported by private equity investment. 

Sterile fill-finish capacity coming during Q3 of 2025.

A headquarters expansion slated for 2025 for biopharmaceutical analytical services.

Dean Bornilla

Articles